logo

Merck & Co Inc. (MRK)



Trade MRK now with
  Date
  Headline
10/23/2017 2:20:48 AM AstraZeneca And Merck Submit NDA To Japan's PMDA For Use Of Lynparza (olaparib) Tablets
10/18/2017 6:49:28 AM Merck Announces Presentation Of Updated OS Findings, Secondary Endpoint, From Phase 3 KEYNOTE-024 Trial
10/18/2017 2:06:56 AM AstraZeneca, Merck Announce FDA Priority Review For Lynparza In Breast Cancer
10/10/2017 8:07:04 AM Merck Presents Six-year Efficacy Data For GARDASIL 9 At EUROGIN 2017 Congress
10/4/2017 8:03:13 AM Merck Highlights Ongoing Commitment To Fighting Infectious Diseases With 40 Data Presentations At ID Week 2017
10/3/2017 6:58:12 AM Merck To Present New Data On ZEPATIER For Chronic Hepatitis C Virus Infection At The Liver Meeting 2017
9/29/2017 6:59:16 AM Merck To Present New And Updated Data Investigating KEYTRUDA (pembrolizumab)
9/29/2017 6:58:08 AM Merck Discontinues MK-3682B And MK-3682C Development Programs For Treatment Of HCV Infection
9/22/2017 3:36:22 PM FDA Approves Merck’s KEYTRUDA For Previously Treated Patients With Metastatic Gastric Cancer